BioPharma Dive7h
Bristol Myers schizophrenia drug, the first of its kind, approved by FDA
In testing, Cobenfy eased schizophrenia symptoms without some of the disruptive side effects typical of existing drugs. The results have been met with excitement, as well as caution.
Crain's Chicago Business12h
Arch Venture Partners closes $3B fund to invest in next-gen biotech startups
Chicago-based venture-capital firm Arch Venture Partners has closed a new $3 billion fund to invest in early-stage ...
Chicago biotech-focused VC firm Arch Venture Partners closes $3 billion fund
A biotech-focused venture capital firm in Chicago is ready with a new fund as life sciences and biotech continue to find new ...
FierceBiotech17h
Arch closes $3B-plus fund as biotech investment environment shows more signs of a revival
On the heels of a $3 billion fund from Bain Capital Life Sciences, Arch Venture Partners is proving it can go toe-to-toe with ...
ARCH Venture Partners Announces New Fund to Create the Next Generation of Biotech Companies
ARCH Venture Partners today announced the closing of ARCH Venture Fund XIII, a venture capital fund with more than $3 billion ...